These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16620968)

  • 1. PRAME is a membrane and cytoplasmic protein aberrantly expressed in chronic lymphocytic leukemia and mantle cell lymphoma.
    Proto-Siqueira R; Figueiredo-Pontes LL; Panepucci RA; Garcia AB; Rizzatti EG; Nascimento FM; Ishikawa HC; Larson RE; Falcão RP; Simpson AJ; Gout I; Filonenko V; Rego EM; Zago MA
    Leuk Res; 2006 Nov; 30(11):1333-9. PubMed ID: 16620968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
    Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
    Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression of PRAME in chronic lymphoproliferative disorders.
    Proto-Siqueira R; Falcão RP; de Souza CA; Ismael SJ; Zago MA
    Leuk Res; 2003 May; 27(5):393-6. PubMed ID: 12620290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PRAME mRNA levels in cases with chronic leukemia: Clinical importance and review of the literature.
    Paydas S; Tanriverdi K; Yavuz S; Seydaoglu G
    Leuk Res; 2007 Mar; 31(3):365-9. PubMed ID: 16914202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guess what: Chronic 13q14.3+/CD5-/CD23+ lymphocytic leukemia in blood and t(11;14)(q13;q32)+/CD5+/CD23- mantle cell lymphoma in lymph nodes!
    Lima M; Pinto L; Dos Anjos Teixeira M; Canelhas A; Mota A; Cabeda JM; Silva C; Queirós ML; Fonseca S; Santos AH; Brochado P; Justiça B
    Cytometry B Clin Cytom; 2003 Jan; 51(1):41-4. PubMed ID: 12500296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
    Santamaría C; Chillón MC; García-Sanz R; Balanzategui A; Sarasquete ME; Alcoceba M; Ramos F; Bernal T; Queizán JA; Peñarrubia MJ; Giraldo P; San Miguel JF; Gonzalez M
    Haematologica; 2008 Dec; 93(12):1797-805. PubMed ID: 18815192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant hypomethylation of the cancer-testis antigen PRAME correlates with PRAME expression in acute myeloid leukemia.
    Ortmann CA; Eisele L; Nückel H; Klein-Hitpass L; Führer A; Dührsen U; Zeschnigk M
    Ann Hematol; 2008 Oct; 87(10):809-18. PubMed ID: 18587578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection and functional analysis of CD8+ T cells specific for PRAME: a target for T-cell therapy.
    Griffioen M; Kessler JH; Borghi M; van Soest RA; van der Minne CE; Nouta J; van der Burg SH; Medema JP; Schrier PI; Falkenburg JH; Osanto S; Melief CJ
    Clin Cancer Res; 2006 May; 12(10):3130-6. PubMed ID: 16707612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The tumor-associated antigen PRAME is universally expressed in high-stage neuroblastoma and associated with poor outcome.
    Oberthuer A; Hero B; Spitz R; Berthold F; Fischer M
    Clin Cancer Res; 2004 Jul; 10(13):4307-13. PubMed ID: 15240516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telomerase (hTERT 611-626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells.
    Kokhaei P; Palma M; Hansson L; Osterborg A; Mellstedt H; Choudhury A
    Exp Hematol; 2007 Feb; 35(2):297-304. PubMed ID: 17258078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of the Rho-family GTPase gene RHOF in lymphocyte subsets and malignant lymphomas.
    Gouw LG; Reading NS; Jenson SD; Lim MS; Elenitoba-Johnson KS
    Br J Haematol; 2005 May; 129(4):531-3. PubMed ID: 15877735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The CD45 isoform B220 identifies select subsets of human B cells and B-cell lymphoproliferative disorders.
    Rodig SJ; Shahsafaei A; Li B; Dorfman DM
    Hum Pathol; 2005 Jan; 36(1):51-7. PubMed ID: 15712182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of PRAME expression causes cell cycle arrest and apoptosis in leukemic cells.
    Tanaka N; Wang YH; Shiseki M; Takanashi M; Motoji T
    Leuk Res; 2011 Sep; 35(9):1219-25. PubMed ID: 21550659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myeloid leukemia cells express tumor-associated antigens eliciting specific CD8+ T-cell responses and are lacking costimulatory molecules.
    Schmitt M; Li L; Giannopoulos K; Chen J; Brunner C; Barth T; Schmitt A; Wiesneth M; Döhner K; Döhner H; Greiner J
    Exp Hematol; 2006 Dec; 34(12):1709-19. PubMed ID: 17157168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative assessment of PRAME expression in diagnosis of childhood acute leukemia.
    Spanaki A; Perdikogianni C; Linardakis E; Kalmanti M
    Leuk Res; 2007 May; 31(5):639-42. PubMed ID: 16860864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of erythropoietin receptor and in vitro functional effects of epoetins in B-cell malignancies.
    Kokhaei P; Abdalla AO; Hansson L; Mikaelsson E; Kubbies M; Haselbeck A; Jernberg-Wiklund H; Mellstedt H; Osterborg A
    Clin Cancer Res; 2007 Jun; 13(12):3536-44. PubMed ID: 17575216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PRAME expression in hairy cell leukemia.
    Arons E; Suntum T; Margulies I; Yuan C; Stetler-Stevenson M; Kreitman RJ
    Leuk Res; 2008 Sep; 32(9):1400-6. PubMed ID: 18295331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
    Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
    Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of RHAMM/CD168 and other tumor-associated antigens in patients with B-cell chronic lymphocytic leukemia.
    Giannopoulos K; Li L; Bojarska-Junak A; Rolinski J; Dmoszynska A; Hus I; Greiner J; Renner C; Döhner H; Schmitt M
    Int J Oncol; 2006 Jul; 29(1):95-103. PubMed ID: 16773189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients.
    Tam CS; Otero-Palacios J; Abruzzo LV; Jorgensen JL; Ferrajoli A; Wierda WG; Lerner S; O'Brien S; Keating MJ
    Br J Haematol; 2008 Apr; 141(1):36-40. PubMed ID: 18324964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.